Endo Health Solutions is exploring “strategic alternatives” for its HealthTronics business and its early-stage drug discovery technology as part of the Malvern, Pa., specialty pharmaceutical company’s effort to focus on its most promising assets. HealthTronics, a Texas-based provider of urological products and services was acquired by Endo for $223 million in 2010. “We have received interest in both, and for HealthTronics, we have engaged an investment bank to assist us with the process,” said Rajiv De Silva, Endo’s president and CEO, in a conference call with stock analysts Tuesday morning, Endo (NASDAQ: ENDP), in a cost-cutting move, cut its workforce by 15 percent, or nearly 700 positions, in June.